Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS)

International Journal of Clinical Practice

Volumn 68, Issue 2, 2014, Pages 180-187

  Devroey, D ^a   Radermecker, R P ^b   Van Der Schueren, B J ^c   Torbeyns, B ^d   Jaken, R J ^d  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d MSD Belgium   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGED; BELGIUM; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DYSLIPIDEMIAS; FEMALE; HUMAN; MALE; METABOLISM; MULTICENTER STUDY; PREVALENCE; RISK FACTOR; TREATMENT OUTCOME;

AGED; BELGIUM; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; MALE; PREVALENCE; RISK FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84893671032     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12315     Document Type: Article

References (30)

1. Wild S, Roglic G, Green A, Sicree R, King H,. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-53.
2. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH,. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006; 113: 898-918.
3. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
4. Capewell S, Morrison CE, McMurray JJ,. Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart 1999; 81: 380-6.
5. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-52.
6. Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217 (Suppl. 1): S1-44.
7. Shah PK, Kaul S, Nilsson J, Cercek B,. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation 2001; 104: 2376-83.
8. Gotto AM Jr,. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J 2002; 144 (6 Suppl.): S33-42.
9. Barter PJ, Puranik R, Rye KA,. New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease. Curr Cardiol Rep 2007; 9: 493-8.
10. McBride P,. Triglycerides and risk for coronary artery disease. Curr Atheroscler Rep 2008; 10: 386-90.
11. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39.
12. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U,. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373: 929-40.
13. Bruckert E, Baccara-Dinet M, McCoy F, Chapman J,. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin 2005; 21: 1927-34.
14. Van Ganse E, Laforest L, Burke T, Phatak H, Souchet T,. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study. Clin Ther 2007; 29: 1671-81.
15. Grant RW, Meigs JB,. Prevalence and treatment of low HDL cholesterol among primary care patients with type 2 diabetes: an unmet challenge for cardiovascular risk reduction. Diabetes Care 2007; 30: 479-84.
16. Goff DC Jr, Bertoni AG, Kramer H, Bonds D, Blumenthal RS, Tsai MY, Psaty BM,. Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation 2006; 113: 647-56.
17. Roberts WC,. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997; 80: 106-7.
18. Maron DJ, Fazio S, Linton MF,. Current perspectives on statins. Circulation 2000; 101: 207-13.
19. Luc G, Bard JM, Ferrières J, et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol 2002; 22: 1155-61.
20. Bourgault C, Davignon J, Fodor G, et al. Statin therapy in Canadian patients with hypercholesterolemia: the Canadian Lipid Study-Observational (CALIPSO). Can J Cardiol 2005; 21: 1187-93.
21. Bruckert E, Baccara-Dinet M, Eschwege E,. Low HDL-cholesterol is common in European Type 2 diabetic patients receiving treatment for dyslipidaemia: data from a pan-European survey. Diabet Med 2007; 24: 388-91.
22. Assmann G, Benecke H, Neiss A, Cullen P, Schulte H, Bestehorn K,. Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results: of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events Including Physicians' Experience and Evaluation). Eur J Cardiovasc Prev Rehabil 2006; 13: 776-83.
23. Yan AT, Yan RT, Tan M, et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 2006; 119: 676-83.
24. Waters DD, Brotons C, Chiang CW, et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009; 120: 28-34.
25. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
26. Jacobson TA,. Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 2008; 83: 687-700.
27. Preiss D, Tikkanen MJ, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2012; 305: 2556-64.
28. Gouni-Berthold I, Mikahilidis DP, Rizzo M,. Clinical benefits of ezetimibe use: is absence of proof, proof of absence? Expert Opin Pharmacother 2012; 13: 1985-8.
29. Berthold HK, Krone W, Erdmann E, Gouni-Berthold I,. Lipid lowering in patients with chronic kidney disease: a SHARP turn in the wrong direction? Eur J Cardiovasc Prev Rehabil 2011; 18: 858-61.
30. Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008; 156: 826-32.